Publication:
Secondary prevention of stroke: Pleiotropic effects of optimal oral pharmacotherapy (review)

dc.contributor.authorKiyoshi Kikuchien_US
dc.contributor.authorKo Ichi Kawaharaen_US
dc.contributor.authorNaoki Miuraen_US
dc.contributor.authorTakashi Itoen_US
dc.contributor.authorYoko Morimotoen_US
dc.contributor.authorSalunya Tancharoenen_US
dc.contributor.authorNobuyuki Takeshigeen_US
dc.contributor.authorHisaaki Uchikadoen_US
dc.contributor.authorRokudai Sakamotoen_US
dc.contributor.authorNaohisa Miyagien_US
dc.contributor.authorChiemi Kikuchien_US
dc.contributor.authorNarumi Iidaen_US
dc.contributor.authorNaoto Shiomien_US
dc.contributor.authorTerukazu Kuramotoen_US
dc.contributor.authorMasaru Hirohataen_US
dc.contributor.authorIkuro Maruyamaen_US
dc.contributor.authorMotohiro Moriokaen_US
dc.contributor.authorEiichiro Tanakaen_US
dc.contributor.otherYame Public Hospitalen_US
dc.contributor.otherKurume University School of Medicineen_US
dc.contributor.otherOsaka Institute of Technologyen_US
dc.contributor.otherKagoshima University Faculty of Medicineen_US
dc.contributor.otherKagoshima Universityen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherNishida Koutoku Hospitalen_US
dc.contributor.otherKohjin Co., Ltd.en_US
dc.contributor.otherSaiseikai Shiga Hospitalen_US
dc.contributor.otherOmuta City General Hospitalen_US
dc.date.accessioned2018-06-11T04:35:53Z
dc.date.available2018-06-11T04:35:53Z
dc.date.issued2012-07-01en_US
dc.description.abstractStroke is a major cause of mortality and disability worldwide. During the past three decades, major advances have occurred in secondary prevention, which have demonstrated the broader potential for the prevention of stroke. Risk factors for stroke include previous stroke or transient ischemic attack, hypertension, high blood cholesterol and diabetes. Proven secondary prevention strategies are antiplatelet agents, antihypertensive drugs, statins and glycemic control. In the present review, we evaluated the secondary prevention of stroke in light of clinical studies and discuss new pleiotropic effects beyond the original effects and emerging clinical evidence, with a focus on the effect of optimal oral pharmacotherapy.en_US
dc.identifier.citationExperimental and Therapeutic Medicine. Vol.4, No.1 (2012), 3-7en_US
dc.identifier.doi10.3892/etm.2012.560en_US
dc.identifier.issn17921015en_US
dc.identifier.issn17920981en_US
dc.identifier.other2-s2.0-84865708761en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/13689
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84865708761&origin=inwarden_US
dc.subjectBiochemistry, Genetics and Molecular Biologyen_US
dc.subjectImmunology and Microbiologyen_US
dc.titleSecondary prevention of stroke: Pleiotropic effects of optimal oral pharmacotherapy (review)en_US
dc.typeReviewen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84865708761&origin=inwarden_US

Files

Collections